Here is Matt Lowdon medtech and biotech deals update, summarising the news I found from last week. Headlines involve implantables, genomics, cancer vaccines, and more. Have a good week :)
🔔 CORXEL Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
🔔 Medtronic has finalized a $90 million investment in Anteris Technologies, a Minnesota-based medtech company focused on advanced structural heart technologies.
🔔 Antwerp-based Agomab has filed for an IPO in the U.S., looking to tap public markets to fund the next stage of development for its pipeline in fibrotic and inflammatory diseases
🔔 QV Bioelectronics, a Cheshire biotech firm that’s aiming to revolutionise treatment for brain cancers has secured £4.5m in funding to bring its world-first technology to clinics.
🔔 Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic.
🔔 UAE-based CE Ventures (CEIIF), the VC arm of Crescent Enterprises, has participated in a $55 million Series A funding round for US-based biotech company Think Bioscience.
🔔 GSK is paying $2.2 billion to buy RAPT Therapeutics and its anti-immunoglobulin E (IgE) antibody to protect against food allergy reactions.
🔔 San Francisco-based Mendra, a biopharma aiming to advance promising therapies for rare disease medicines, has announced its launch with the closing of an $82m Series A financing.
🔔 Genomics and life sciences pioneer J. Craig Venter, Ph.D., is back with a new JCVI spinoff that’s looking to shake up the world of diagnostics and genomic sequencing. Diploid Genomics, Inc.
🔔 UK biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class ADC, EP0028, for solid tumors.
🔔 Infinitopes, a U.K. cancer vaccine biotech spun out of Cancer Research U.K. and the University of Oxford, has expanded its seed round to $35.1m
🔔 The French preclinical-stage biotech ErVimmune closed a €17 million series A round to bring its lead candidate cancer vaccine into the clinic.
🔔 Zylox-Tonbridge, a Hong Kong-listed company specialising in neurovascular and peripheral vascular interventional products, has agreed to acquire German medical technology company optimed.
🔔 Heidelberg-based EXCIVA GmbH secures €51M to tackle agitation in Alzheimer’s care